Home ::> Commercialization Main ::> Juventas Therapeutics

Commercialization: Juventas Therapeutics (formerly AcelleRX Therapeutics)

The Center for Stem Cell and Regenerative Medicine completed its second business spin-out during September 2004.

Juventas Therapeutics is developing novel regenerative medicine technologies discovered by Cleveland Clinic Cardiologist Marc Penn, M.D., Ph.D. for treatment of cardiovascular disease.  The company’s lead product, Stromal Derived Factor-1 (SDF-1) significantly increases cardiac function through promoting cell survival and revascularization post myocardial infarction (MI).  Driven by several animal studies demonstrating that SDF-1 significantly enhances the efficacy of a broad range of cell therapies currently in clinical trials for treatment of cardiovascular disease, the company’s first generation SDF-1 platform is based on cell based gene therapy methods that will employ engineered cells to deliver SDF-1 to damaged myocardium.  Through a strategic partnership with a leading cell therapy company, they are moving this platform towards a Phase I clinical trial for treatment of chronic heart failure (CHF) with SDF-1 expressing skeletal myoblasts.  Recent data also suggests that SDF-1 can also be delivered through non-cell based delivery methods providing a cheaper, logistically more manageable second generation alternative to current cell therapy initiatives.

For more information on Juventas Therapeutics please contact Rahul Aras at 216-445-0830 or Rahul@Juventasinc.com.